Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Glyxambi (empagliflozin/linagliptin) and Onglyza (saxagliptin) are both medications used to treat Type 2 diabetes, but they have some key differences. Glyxambi is a combination of two drugs: empagliflozin, an SGLT2 inhibitor, and linagliptin, a DPP-4 inhibitor. Onglyza, on the other hand, contains only saxagliptin, which is also a DPP-4 inhibitor. Glyxambi not only helps control blood sugar but also lowers the risk of death from heart disease in people with Type 2 diabetes and heart disease. Onglyza does not have this additional heart benefit. Glyxambi is taken once daily in the morning, while Onglyza can be taken at any time of day. Both medications can cause urinary tract infection, but Glyxambi can also cause more frequent urination. Additionally, Onglyza is available in a generic form, while Glyxambi is not.
Saxagliptin (Onglyza) is an add-on medication to exercise and a balanced, nutritious diet to improve blood sugar control in adults with Type 2 diabetes. It belongs to the drug class called dipeptidyl peptidase-4 (DPP-4) inhibitors. The saxagliptin (Onglyza) dosage is taken by mouth once daily. Possible side effects include certain infections and headaches. The brand name, Onglyza, is no longer available. But the lower-cost generic version is still available.